NovoCure (NVCR) Total Liabilities (2014 - 2026)

NovoCure (NVCR) has reported Total Liabilities for 13 consecutive years, with $457.1 million the latest figure, recorded in Q2 2026.

• Quarterly Total Liabilities fell 49.01% year-over-year to $457.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $457.1 million (down 49.01% YoY) and the FY2025 annual result came in at $463.9 million, down 47.32% from the prior year.
• Total Liabilities held at $457.1 million in Q2 2026 per NVCR's latest filing, from $457.2 million in the prior quarter.
• Over the last five years, Total Liabilities for NVCR reached as high as $1.0 billion in Q3 2025 and fell as low as $457.1 million in Q2 2026.
• A 5-year average of $748.4 million and a median of $751.6 million in 2022 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2025 — Total Liabilities increased 18.42% — and 2026, when it slumped 49.01%.
• Year by year, Total Liabilities stood at $750.5 million in 2022, then gained by 4.42% to $783.6 million in 2023, then gained by 12.37% to $880.6 million in 2024, then sank by 47.32% to $463.9 million in 2025, then slipped by 1.46% to $457.1 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $457.1 million, $457.2 million, and $463.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.